Anti-CD28 compositions
AssigneeXencor, Inc.
InventorsJohn R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Life of this patent
Estimating the term…
Abstract
Provided herein are novel anti-CD28 x anti-B7H3 (also referred to as “αCD28 x αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers. Subject αCD28 x αB7H3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and targeting to B7H3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful for enhancing anti-tumor activity when used in combination with other anti-cancer therapies.
Claims10
A construct comprising a CD28 antigen binding domain (ABD), the CD28 binding domain comprising:
- a) a variable heavy domain (VH) the amino acid sequence of SEQ ID NO:880, and b) a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.
A nucleic acid composition comprising:
- a) a first nucleic acid encoding a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880;
- and
- b) a second nucleic acid encoding a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.
An expression vector composition comprising:
- a) a first expression vector comprising a first nucleic acid encoding a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880;
- and
- b) a second expression vector comprising the second nucleic acid encoding a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.
An antibody comprising a CD28 binding domain, wherein the CD28 binding domain comprises:
- a) a variable heavy domain (VH) having the amino acid sequence of SEQ ID NO:880, and b) a variable light domain (VL) having the amino acid sequence of SEQ ID NO:874.
Dependencies are inferred from the claim text.